Bifogade filer
Ascelia Pharma Presents Orviglance SPARKLE Study Primary Results as Cutting-Edge Research at the 2024 RSNA Annual Meeting
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Ascelia Pharma AB (publ) (ticker: ACE) today presents the primary results from the Orviglance® phase 3 SPARKLE Study as an oral presentation at the world’s largest radiology conference, RSNA, in Chicago.
As communicated earlier, in the successful SPARKLE study, Orviglance significantly improved the visualization of focal liver lesions compared to unenhanced MRI in patients with suspected or known liver lesions and severe kidney impairment.
The results were accepted as an oral presentation at the 2024 annual conference of the Radiological Society of North America, the world’s largest radiology conference. The presentation was accepted in the Cutting-Edge Research category and will be presented today by Dr. Alvin Silva, SPARKLE Principal Investigator and Professor of Radiology, Mayo Clinic, Phoenix, United States.
- Title of presentation: SPARKLE: A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of ACE-MBCA in Patients with Known or Suspected Focal Liver Lesions and Severe Renal Impairment
- Timing of presentation: 2 Dec, 13:30-14:00 CDT, local time Chicago